In the phase II HORIZON-Lung study conducted in China, 94 pretreated patients with HER2 MUT NSCLC achieved an ORR of 73% and a mPFS of 11.5 months; OS data was not mature. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.